New hope for stubborn high blood pressure? phase 3 trial launches
NCT ID NCT07635914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests aprocitentan, a drug already approved in some countries, for people with resistant hypertension—high blood pressure that stays high despite taking three or more medications. About 382 adults will receive either the drug or a placebo for 8 weeks. The main goal is to see if aprocitentan can safely lower sitting systolic blood pressure more than placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aprocitentan tablets
- What this could lead to
- If it works, this could offer a new treatment option for people whose blood pressure remains high despite taking multiple medications.
- What could go wrong
- This is a Phase 3 trial, but it is not yet recruiting. The drug may not lower blood pressure significantly more than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESISTANT HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple heart-rate test reveal who is truly taking their blood pressure pills?
- Talking to a nurse may ease blood pressure pill side effects
- New study seeks to identify who benefits from Last-Resort blood pressure drugs
- Skin blood flow test may predict heart danger in tough-to-treat high blood pressure
- Beetroot breakthrough? new study tests natural BP fix for tough hypertension
- Kidney nerve procedure tested for stubborn high blood pressure